CHRM4 and prostate cancer: Our findings suggest that ADT-induced CHRM4 may activate AKT/MYCN signaling to induce IFNA17 secretion and upregulate immune checkpoints in the TME to drive potential immunosuppressive responses, leading to NED and metastasis in prostate cancer.